Seres Therapeutics (NASDAQ:MCRB) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a strong sell rating in a report issued on Saturday morning.

Several other equities research analysts also recently commented on the company. Canaccord Genuity Group restated a “buy” rating and set a $22.00 price objective on shares of Seres Therapeutics in a report on Friday, March 13th. Weiss Ratings restated a “sell (d)” rating on shares of Seres Therapeutics in a report on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Seres Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $22.00.

Seres Therapeutics Stock Performance

Shares of MCRB opened at $7.70 on Friday. Seres Therapeutics has a 52-week low of $6.53 and a 52-week high of $29.98. The business’s 50 day moving average price is $8.65 and its two-hundred day moving average price is $13.05. The firm has a market cap of $74.54 million, a PE ratio of -1.49 and a beta of 0.12.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($2.08) EPS for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The firm had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $0.36 million.

Institutional Investors Weigh In On Seres Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Seres Therapeutics by 6.8% during the third quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock valued at $6,001,000 after acquiring an additional 19,793 shares in the last quarter. Invesco Ltd. grew its holdings in Seres Therapeutics by 193.2% during the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock worth $96,000 after buying an additional 89,995 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in Seres Therapeutics by 4.8% during the fourth quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock worth $1,536,000 after buying an additional 4,723 shares in the last quarter. Marshall Wace LLP bought a new stake in Seres Therapeutics during the second quarter worth $1,016,000. Finally, Geode Capital Management LLC grew its holdings in Seres Therapeutics by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after buying an additional 1,160 shares in the last quarter. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.